Recent advances in targeted strategies for triple-negative breast cancer

Zhu, Shuangli; Wu, Yuze; Song, Bin; Yi, Ming; Yan, Yuheng; Mei, Qi; Wu, Kongming

doi:10.1186/s13045-023-01497-3

Journal of Hematology & Oncology

Table 5 The clinical trials of VEGF/VEGFR inhibitors in TNBC

From: Recent advances in targeted strategies for triple-negative breast cancer

Drug name	Com	Num	Regiments	Ph	State	Object	POM	NCT number
Bevacizumab		54	15 mg/ kg	II	Completed	mTNBC	PFS	NCT03577743
Bevacizumab		2591	5 mg/kg q1w	III	Completed	TNBC	IDFS	NCT00528567
Bevacizumab	Albumin-bound paclitaxel	128	Bevacizumab: 7.5 mg/kg iv q3w Albumin-bound paclitaxel: 260 mg/m² iv q3w	II	Recruiting	mTNBC	PFS	NCT05192798
Bevacizumab	Tirelizumab	15	Bevacizumab: 7.5 mg/kg iv q3w Tirelizumab: 200 mg iv q3w	II	Recruiting	mTNBC	ORR	NCT05303038
Bevacizumab	Liposomal doxorubicin hydrochloride/ Everolimus	17	Bevacizumab: iv over 90 min on day 1 Liposomal doxorubicin hydrochloride: iv over about 3 h on day 1 Everolimus: po qd on days 1–21	II	Active, not recruiting	Advanced TNBC	pCR	NCT02456857
Bevacizumab	Paclitaxel/ Docetaxel	49	Bevacizumab: 10 mg/kg iv q2w Paclitaxel q1w or docetaxel q3w	IV	Completed	TNBC	PFS	NCT01094184
Bevacizumab	Docetaxel, Carboplatin	45	Bevacizumab: 7.5 mg/kg iv q3w Docetaxel iv and carboplatin iv	II	Completed	TNBC	pCR	NCT01208480
Bevacizumab	Nab-paclitaxel, erlotinib	59	Bevacizumab: iv over 30–90 min on days 1,15 Nab-paclitaxel: iv on days 1, 8, and 15 erlotinib hydrochloride: po qd	II	Completed	TNBC	PFS	NCT00733408
Bevacizumab	Abraxane, Carboplatin	41	Bevacizumab: 10 mg/kg iv on days 1,15 Abraxane: 100 mg/m² iv over 30 min on days 1,8,15 Carboplatin: AUC = 2 iv over 15 min on days 1,8,15	II	Completed	mTNBC	CBR	NCT00479674
Apatinib	Camrelizumab	58	Apatinib:250 mg po qd Camrelizumab: 200 mg iv on day 1	II	Recruiting	TNBC	pCR	NCT05556200
Apatinib	Camrelizumab and nab-paclitaxel	35	Apatinib:250 mg po qd Camrelizumab: 200 mg iv q2w Nab-paclitaxel: 125 mg/m² iv q1w	II	Not yet recruiting	TNBC	pCR	NCT05447702
Apatinib	Paclitaxel and Carboplatin	29	Apatinib: 250 mg po qd on day 1-14 Paclitaxel: 175 mg/m² on day 1 Carboplatin: AUC = 4 on day 1,14	II	Unknown	TNBC	pCR	NCT03735082
Apatinib	Capecitabine	80	Apatinib: 425 mg on day 1-21 Capecitabine: 1000 mg/m² bid on day 1-14	II	Recruiting	Advanced TNBC	PFS	NCT03775928
Apatinib	Paclitaxel	20	Apatinib: 500 mg po qd 12 weeks Paclitaxel: 80 mg/m² on day 1 q1w	II	Recruiting	Advanced TNBC	ORR	NCT03348098
Apatinib	Albumin paclitaxel and carboplatin	60	Apatinib: 250 mg po on day 1–21 Albumin paclitaxel: 260 mg/m² iv on day 1 Carboplatin: AUC = 5–6 iv on day 1	II	Recruiting	TNBC	pCR	NCT03650738
Apatinib	Camrelizumab and Eribulin	46	Apatinib: 250 mg/d po on day 1-21 Camrelizumab: 200 mg iv q3w Eribulin: 1.4 mg/m² iv on day 1, 8 q3w	II	Active, not recruiting	Advanced TNBC	ORR	NCT04303741

mTNBC: metastatic triple negative breast cancer; PFS: progression-free survival; IDFS: invasive disease-free survival; ORR: overall response rate; pCR: pathologic complete response; CBR: clinical benefit rate

Back to article page

ISSN: 1756-8722

Contact us

General enquiries: journalsubmissions@springernature.com